share_log

BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE

BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE

BioVaxys 宣佈允許美國獲得 DPX 配方專利,並針對第一階段 DPX Surmage 提交更多國際專利申請
PR Newswire ·  04/03 20:02

VANCOUVER, B.C., April 3, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a Patent ("Patent") for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX. Part of the extensive Intellectual Property portfolio acquired by BioVaxys from the former IMV, Inc, this Patent was recently allowed in Japan and is currently pending in the European Union.

不列顛哥倫比亞省溫哥華,2024年4月3日 /PRNewswire/ — BioVaxys Technology Corp.(CSE:BIOV)(FRA:5LB)(OTCQB:BVAXF)(“BioVaxys” 或 “公司”)宣佈,它已收到美國專利商標局(“USPTO”)發出的誘導免疫抗體的專利(“專利”)許可通知使用DPX配製的B細胞表位的低劑量體積輸送所產生的反應。該專利是BioVaxys從前IMV, Inc手中收購的廣泛知識產權組合的一部分,最近在日本獲得批准,目前正在歐盟待批。

DPX is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules. Its unique "no release" mechanism of action allows antigen presenting cells (APCs) to be attracted to the injection site, facilitating a robust and sustained immune response.

DPX 是一種專有的基於脂質的遞送平台,不含水成分,可使用一系列包裝的抗原、蛋白質、肽、mRNA 或小分子配製。其獨特的 “不釋放” 作用機制允許抗原呈遞細胞(APC)被吸引到注射部位,從而促進強大而持續的免疫反應。

The smallest dose of a currently approved vaccine is 0.1ml for Sanofi-Pasteur's Fluzone Intradermal Quadrivalent vaccine. Low dose volume delivery of DPX formulated B-cell epitope is designed to be delivered in single dose as low as 50μL to 90 μL.

目前批准的賽諾菲-巴斯德Fluzone皮內四價疫苗的最小劑量爲0.1ml。DPX 配製的 B 細胞表位的低劑量體積輸送設計爲以低至 50μL 至 90 μL 的單劑量輸送。

An epitope is the part of an antigen that the host's immune system recognizes, eliciting the immune response to an invading pathogen. It specifically binds to the corresponding antigen receptor on the immune cell (such as a B-cell). Whereas T-cells protect people from getting infected by destroying cancerous and infected cells, B-cells produce antibodies to fight infection.

表位是宿主免疫系統識別的抗原部分,可激發對入侵病原體的免疫反應。它與免疫細胞(例如B細胞)上相應的抗原受體特異性結合。T細胞通過破壞癌細胞和受感染細胞來保護人們免受感染,而B細胞則產生抗體來抵抗感染。

BioVaxys President and Chief Operating Officer Kenneth Kovan stated "Allowance of this important patent in the United States greatly expands the value of our IP and antigen delivery platform with potential partners. Having the unique ability to deliver B cell epitopes using a low dose DPX formulation is an attractive approach for packaging antigens for a range of cancer immunotherapeutics and therapeutic vaccines."

BioVaxys總裁兼首席運營官肯尼思·科文表示:“美國對這項重要專利的允許極大地擴大了我們與潛在合作伙伴的知識產權和抗原交付平台的價值。具有使用低劑量DPX配方輸送B細胞表位的獨特能力,是包裝一系列癌症免疫療法和治療性疫苗抗原的一種有吸引力的方法。”

BioVaxys also is pleased to announce it has entered the national phase in the United States, Canada, European Union, Japan, and Australia with its patent application for DPX-survivin/MAGE A9 ("DPX SurMAGE"), a DPX formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy.

BioVaxys還高興地宣佈,其DPX-Survivin/MAGE A9(“DPX Surmage”)(一種腫瘤相關抗原生存素的DPX配方)和作爲雙靶免疫療法的MAGE A9的專利申請已進入美國、加拿大、歐盟、日本和澳大利亞的國家階段。

The survivins and MAGE-A9 are frequently over-expressed in various human cancers including bladder, lung and kidney, and correlate with a resistance to chemotherapy and aggressiveness of tumors, and both are recognized as important targets for cancer vaccines and therapeutics.

在包括膀胱癌、肺癌和腎臟癌在內的各種人類癌症中,存活素和 MAGE-A9 經常過度表達,並與腫瘤的耐藥性和侵襲性相關,兩者都被認爲是癌症疫苗和治療的重要靶標。

DPX SurMAGE" recently completed a successful Phase I clinical study in Canada with bladder cancer patients conducted at CHU de Québec-Université Laval, and induced a robust peptide-specific T cell response. Kovan further added that "BioVaxys and the Phase 1 clinical study investigators see the potential with further evaluation of DPX SurMAGE, and are particularly excited by the proven ability of DPX to package multiple different antigens. We will be reconvening with the study team at CHU de Québec-Université Laval to plan further development."

DPX Surmage” 最近在加拿大成功完成了一項針對膀胱癌患者的I期臨床研究,該研究在魁北克大學拉瓦爾分校進行,並誘發了強大的肽特異性T細胞反應。科文進一步補充說:“BioVaxys和1期臨床研究的研究人員看到了進一步評估DPX Surmage的潛力,他們對DPX包裝多種不同抗原的經過驗證的能力感到特別興奮。我們將與魁北克大學拉瓦爾分校的研究小組再次會面,以規劃進一步的發展。”

About BioVaxys Technology Corp.

關於 BioVaxys 科技公司

BioVaxys Technology Corp. (), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

BioVaxys Technology Corp. () 是一家在加拿大不列顛哥倫比亞省註冊的生物製藥公司,是一家臨床階段的生物製藥公司,致力於通過基於DPX免疫教育技術平台及其用於治療癌症、傳染病、抗原脫敏和其他免疫學領域的Haptenix “新抗原” 腫瘤細胞構建平台的新型免疫療法改善患者生活。該公司的臨床階段產品線包括MaveropePimut-S,它正處於晚期復發難治性瀰漫性大B細胞淋巴瘤(DLBCL)和耐鉑性卵巢癌的二期臨床開發,以及使用其專有的Haptenix “新抗原” 腫瘤細胞構建平台的個性化免疫治療疫苗,該平台即將在西班牙進入I期,用於治療屈光晚期卵巢癌。BVX-0918

The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.

該公司還利用其腫瘤免疫學專業知識,利用其個性化免疫治療疫苗創建了獨特的T淋巴細胞和其他數據集庫,以利用預測算法和其他技術來識別新的可靶向腫瘤抗原。

BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.

BioVaxys的普通股在CSE上市,股票代碼爲 “BIOV”,並在法蘭克福證券交易所(FRA:5LB)和美國(場外交易代碼:BVAXF)上市。欲了解更多信息,請訪問並通過 X 和 LinkedIn 聯繫我們。

ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
+1 646 452 7054

代表董事會
簽名 “詹姆斯·帕森”
首席執行官詹姆斯·帕辛先生
+1 646 452 7054

SOURCE BioVaxys Technology Corp.

來源 bioVaxys 科技公司

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論